Esperion Therapeutics (NASDAQ:ESPR)‘s stock had its “neutral” rating reissued by research analysts at Chardan Capital in a report issued on Tuesday. They presently have a $75.00 price objective on the biopharmaceutical company’s stock, up from their previous price objective of $20.00. Chardan Capital’s target price would suggest a potential upside of 27.88% from the stock’s current price.

The analysts wrote, “We see numerous reasons for our new positive bias, including: A path forward for both BA and a BA+ezetimibe (BA+eze) fixed dose combo (FDC) has been confirmed by the FDA. A definition of statin intolerance has also been agreed on by the FDA. KOLs (e.g. Dr. Nissen) support the need for therapies for patients who are (or believe themselves to be) statin intolerant and refuse statins. CANTOS suggests BA’s high-sensitivity C-reactive protein (hsCRP) lowering effect is highly relevant for CV event reduction and outcomes. Newly-disclosed integrated phase II results suggest sound BA safety. A larger market opportunity results from a pivotal BA phase III design that includes patients “on any statin dose.” Limited use of PCSK9 inhibitors, due to pricing, opens an opportunity. Merck’s (unrated) decision not to file anacetrapib for approval further confirms oral CETP inhibitors as uninteresting assets or competitors.””

Other equities research analysts have also issued research reports about the company. Northland Securities assumed coverage on Esperion Therapeutics in a research report on Tuesday, August 29th. They issued an “outperform” rating and a $72.00 price objective on the stock. Jefferies Group reiterated a “buy” rating and set a $85.00 target price on shares of Esperion Therapeutics in a research report on Monday, August 21st. Zacks Investment Research upgraded Esperion Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, August 23rd. Cowen began coverage on Esperion Therapeutics in a research note on Thursday, September 7th. They issued an “outperform” rating and a $64.00 price objective for the company. Finally, Needham & Company LLC raised their target price on Esperion Therapeutics from $58.00 to $72.00 and gave the company a “positive” rating in a report on Tuesday, August 8th. Seven investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Esperion Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $60.15.

Esperion Therapeutics (ESPR) traded down $2.01 during midday trading on Tuesday, reaching $58.65. 422,500 shares of the company’s stock traded hands, compared to its average volume of 1,022,913. Esperion Therapeutics has a 52 week low of $10.71 and a 52 week high of $65.20.

Esperion Therapeutics (NASDAQ:ESPR) last announced its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.86) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.79) by ($0.07). During the same period last year, the company posted ($0.77) EPS. equities analysts anticipate that Esperion Therapeutics will post -7.21 EPS for the current fiscal year.

Institutional investors have recently bought and sold shares of the stock. Tower Research Capital LLC TRC boosted its position in Esperion Therapeutics by 69,371.4% during the second quarter. Tower Research Capital LLC TRC now owns 4,863 shares of the biopharmaceutical company’s stock worth $225,000 after purchasing an additional 4,856 shares in the last quarter. Aperio Group LLC purchased a new stake in Esperion Therapeutics during the second quarter worth $249,000. SG Americas Securities LLC boosted its position in Esperion Therapeutics by 74.5% during the second quarter. SG Americas Securities LLC now owns 7,008 shares of the biopharmaceutical company’s stock worth $324,000 after purchasing an additional 2,991 shares in the last quarter. Voya Investment Management LLC boosted its position in Esperion Therapeutics by 12.7% during the second quarter. Voya Investment Management LLC now owns 7,148 shares of the biopharmaceutical company’s stock worth $331,000 after purchasing an additional 806 shares in the last quarter. Finally, Metropolitan Life Insurance Co. NY purchased a new stake in Esperion Therapeutics during the first quarter worth $385,000. Hedge funds and other institutional investors own 92.27% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Esperion Therapeutics (ESPR) Earns Neutral Rating from Chardan Capital” was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/12/05/esperion-therapeutics-espr-hold-rating-reiterated-at-chardan-capital.html.

About Esperion Therapeutics

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Analyst Recommendations for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.